Loading stock data...

Piramal Pharma Limited

NSE: PPLPHARMA BSE: PPLPHARMA

NSE
187.49 1.09 (0.58%)

Prev Close

186.4

Open Price

186.4

Volume

3,572,225

Today Low / High

186.11 / 190.8

52 WK Low / High

181.73 / 283.9

Range

178 - 197

BSE
187.35 0.90 (0.48%)

Prev Close

186.45

Open Price

186.15

Volume

116,569

Today Low / High

186.15 / 190.8

52 WK Low / High

180.35 / 283.8

Range

178 - 197

The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 187.49 (target range: 178 - 197), reflecting a change of 1.09 (0.58476%). On the BSE, it is listed at 187.35 (target range: 178 - 197), showing a change of 0.9 (0.4827%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.

28 Nov 186.40 0.43%
27 Nov 188.75 -1.25%
26 Nov 185.50 1.01%
25 Nov 186.00 -0.61%
24 Nov 188.38 -1.09%
21 Nov 190.15 -0.93%
19 Nov 192.95 -2.15%
18 Nov 195.47 -1.71%
17 Nov 194.99 0.25%
14 Nov 193.84 0.10%
13 Nov 195.90 -1.05%
12 Nov 195.00 0.33%
11 Nov 195.40 -0.60%
10 Nov 199.25 -1.91%
07 Nov 198.60 0.28%
06 Nov 196.50 1.44%
04 Nov 201.49 -0.53%
03 Nov 199.76 0.90%

Piramal Pharma Limited Graph

Piramal Pharma Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges

If you are looking for the target price for Piramal Pharma Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 187.49, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.

Scenario Price Target Range
Bullish Scenario 187.35 189.22 170.30 - 208.15
191.10 152.88 - 229.32
192.97 135.08 - 250.86
Bearish Scenario 187.35 185.48 166.93 - 204.02
183.60 146.88 - 220.32
181.73 127.21 - 236.25

Overview of Piramal Pharma Limited

ISIN

INE0DK501011

Industry

Biotechnology

Vol.Avg

3,562,529

Market Cap

248,061,844,954

Last Dividend

0.14

Official Website

Visit Website

IPO Date

2022-10-19

DCF Diff

325.53

DCF

-138

Financial Ratios Every Investor Needs

Stock Dividend of PPLPHARMA

Date Label Adj Dividend Dividend Record Date Payment Date Declaration Date
2025-07-16 July 16, 25 0.14 0.14 2025-07-16 2025-08-29
2024-07-12 July 12, 24 0.11 0.11 2024-07-12 2024-08-25

Stock Rating Details for PPLPHARMA

Metric Value Recommendation
Overall Rating D+ Strong Sell
DCF Score 1 Strong Sell
ROE Score 1 Strong Sell
ROA Score 1 Strong Sell
Debt-to-Equity (DE) Score 1 Strong Sell
Price-to-Earnings (PE) Score 1 Strong Sell
Price-to-Book (PB) Score 2 Sell

Annual Financial Income Report

Date Revenue Co.Rev GP GPR R&D Expenses G&A Expenses Operating Income Net Income EPS EBITDA NIR
2025-03-31 9,151.18 Cr 3,231.65 Cr 5,919.53 Cr 0.6469 0.00 Cr 2,340.38 Cr 3,612.06 Cr 91.13 Cr 0.69 1,404.01 Cr 0.0100
2024-03-31 8,171.16 Cr 3,261.71 Cr 4,909.45 Cr 0.6008 100.67 Cr 262.75 Cr 519.75 Cr 17.82 Cr 0.14 1,366.81 Cr 0.0022
2023-03-31 7,081.55 Cr 5,983.52 Cr 1,098.03 Cr 0.1551 86.36 Cr 231.69 Cr -35.98 Cr -186.46 Cr -1.54 846.35 Cr -0.0263
2022-03-31 6,559.10 Cr 5,178.79 Cr 1,380.31 Cr 0.2104 128.34 Cr 191.21 Cr 373.64 Cr 375.96 Cr 3.11 1,259.94 Cr 0.0573
2021-03-31 5,886.78 Cr 2,073.55 Cr 3,813.22 Cr 0.6478 69.14 Cr 53.85 Cr 2,245.54 Cr 571.50 Cr 4.70 1,296.99 Cr 0.0971

Annual Financials Balance Sheet

Date C&C Equ. Tot. Assets Tot. Liab. Stock. Equity Tot. Debt Net Debt Inv. PP&E (Net) Curr. Def. Rev. Non-Curr. Def. Rev. LT Invest. Curr. Liab.
2025-03-31 501.46 Cr 15,677.59 Cr 7,552.12 Cr 8,125.4700 Cr 4,856.47 Cr 4,355.01 Cr 2,312.70 Cr 5,023.49 Cr 0.00 Cr 175.61 Cr 271.09 Cr 3,766.2700 Cr
2024-03-31 356.82 Cr 15,311.81 Cr 7,400.44 Cr 7,911.3700 Cr 4,710.16 Cr 4,353.34 Cr 2,175.88 Cr 4,815.96 Cr 343.62 Cr 167.90 Cr 240.26 Cr 4,369.3000 Cr
2023-03-31 195.59 Cr 14,522.56 Cr 7,749.06 Cr 6,773.5000 Cr 5,637.08 Cr 5,441.49 Cr 1,681.37 Cr 4,441.44 Cr 201.13 Cr 175.58 Cr 211.87 Cr 3,843.0500 Cr
2022-03-31 228.10 Cr 12,797.04 Cr 6,100.44 Cr 6,696.6000 Cr 4,127.92 Cr 3,899.82 Cr 1,388.80 Cr 3,715.74 Cr 185.19 Cr 150.47 Cr 340.91 Cr 3,033.3400 Cr
2021-03-31 146.73 Cr 5,756.67 Cr 1,656.05 Cr 4,100.6200 Cr 174.26 Cr 27.53 Cr 420.88 Cr 3,166.27 Cr 0.00 Cr 0.00 Cr 122.67 Cr 1,471.6700 Cr

Annual Financials Cash Flow Statement

Date Operating Cash Investing Cash Financing Cash Free Cash Cash Change Cash at End CapEx Income Debt Repay Dividends Inventory
2025-03-31 892.3000 Cr -477.4600 Cr -440.8300 Cr 227.9200 Cr -36.8700 Cr 182.3200 Cr -664.3800 Cr 91.1300 Cr 48.7100 Cr -14.4700 Cr -197.1200 Cr
2024-03-31 1,004.5400 Cr -434.0100 Cr -422.3600 Cr 292.5000 Cr 165.9600 Cr 219.1900 Cr -712.0400 Cr 17.8200 Cr -971.5300 Cr 0.0000 Cr -531.7500 Cr
2023-03-31 483.8900 Cr -1,338.7800 Cr 817.7900 Cr -480.8600 Cr -31.9500 Cr 53.2300 Cr -964.7500 Cr -160.5600 Cr 1,198.4200 Cr -67.0000 Cr -172.6400 Cr
2022-03-31 766.4200 Cr -1,812.1000 Cr 794.1900 Cr -123.0900 Cr -176.7900 Cr 85.1800 Cr -889.5100 Cr 436.7000 Cr 1,019.1300 Cr -50.0000 Cr -60.3300 Cr
2021-03-31 34.7200 Cr -4,382.8900 Cr 4,494.1600 Cr -23.3900 Cr 145.9900 Cr 146.7300 Cr -58.1100 Cr 349.1100 Cr 90.3800 Cr 0.0000 Cr 95.3600 Cr

Quarterly Financial Income Report

Date Revenue Co.Rev GP GPR Operating Income Net Income EPS EBITDA NIR
2025-09-30 2,043.72 Cr 1,516.80 Cr 526.92 Cr 0.2578 -44.15 Cr -99.22 Cr -0.75 224.29 Cr -0.0485
2025-06-30 1,933.71 Cr 694.05 Cr 1,239.66 Cr 0.6411 -90.58 Cr -81.70 Cr -0.62 204.41 Cr -0.0423
2025-03-31 2,754.07 Cr -561.01 Cr 3,315.08 Cr 1.2037 3,301.80 Cr 153.50 Cr 1.16 512.11 Cr 0.0557
2024-12-31 2,204.22 Cr 805.83 Cr 1,398.39 Cr 0.6344 140.93 Cr 3.68 Cr 0.03 366.92 Cr 0.0017
2024-09-30 2,241.75 Cr 1,548.22 Cr 693.53 Cr 0.3094 149.39 Cr 22.59 Cr 0.17 402.72 Cr 0.0101

Quarterly Financials Balance Sheet

Date Cash & Equiv. Short-Term Inv. Cash & Short-Term Net Receivables Inventory Total Curr. Assets PP&E (Net) Total Assets Total Liabilities
2025-09-30 521.58 Cr 222.48 Cr 744.06 Cr 1,984.59 Cr 2,742.83 Cr 5,953.02 Cr 5,221.86 Cr 16,189.43 Cr 8,115.64 Cr
2025-06-30 0.00 Cr 0.00 Cr 408.50 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr -8,125.47 Cr
2025-03-31 501.46 Cr 19.56 Cr 521.02 Cr 2,349.52 Cr 2,312.70 Cr 5,796.99 Cr 5,023.49 Cr 15,677.59 Cr 7,552.12 Cr
2024-12-31 0.00 Cr 0.00 Cr 408.41 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr -7,907.17 Cr
2024-09-30 398.01 Cr 10.40 Cr 408.41 Cr 1,827.14 Cr 2,447.43 Cr 5,381.66 Cr 4,918.75 Cr 15,241.74 Cr 7,334.57 Cr

Quarterly Financials Cash Flow Statement

Date Net Income Operating Cash Flow Investing Cash Flow Financing Cash Flow Net Cash Change Cash at End Cash at Beginning CapEx Free Cash Flow
2025-06-30 -81.70 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr
2025-03-31 153.50 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr
2024-12-31 3.68 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr
2024-09-30 22.59 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr
2024-06-30 -88.64 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr

Splits History

Date Label Split Ratio
2023-08-02 August 02, 23 1023:1000

Similar Stocks: Biotechnology

Company Name Symbol Price Market Cap Volume
Biocon Limited BIOCON ₹398.60 ₹532,161,291,208.00 ₹2,397,734.00
Anthem Biosciences Ltd. ANTHEM ₹636.00 ₹357,183,992,436.00 ₹542,663.00
Syngene International Limited SYNGENE ₹646.50 ₹259,709,334,522.00 ₹408,631.00
Piramal Pharma Limited PPLPHARMA ₹187.49 ₹248,061,844,954.00 ₹3,572,225.00
Onesource Specialty Pharma Ltd. ONESOURCE ₹1,533.00 ₹175,567,156,128.00 ₹483,483.00
Concord Biotech Limited CONCORDBIO ₹1,418.20 ₹148,366,700,513.00 ₹82,980.00
Jubilant Ingrevia Limited JUBLINGREA ₹707.00 ₹111,686,783,740.00 ₹100,253.00
Blue Jet Healthcare Limited BLUEJET ₹579.90 ₹100,592,599,958.00 ₹287,313.00
Supriya Lifescience Limited SUPRIYA ₹745.50 ₹59,999,927,400.00 ₹249,341.00
Zota Health Care Limited ZOTA ₹1,582.00 ₹47,986,260,210.00 ₹52,058.00
Dishman Carbogen Amcis Limited DCAL ₹239.65 ₹37,573,068,717.00 ₹133,070.00

Key Executives

Company Secretary & Compliance Officer
Ms. Tanya Sanish

Gender: female

Year Born:

Vice President of Sales
Prashanth M. S.

Gender: Not Specified

Year Born: 1973

General Counsel
Mr. Sandeep K. Rathod

Gender: male

Year Born:

Chief Executive Officer of Piramal Global Pharma & Director
Mr. Peter Daniel DeYoung

Gender: male

Year Born: 1978

President & Group Chief Information Officer of Piramal Group
Mr. Viral Gandhi

Gender: male

Year Born: 1974

Chief Human Resources Officer
Ms. Puneet Rajput

Gender: female

Year Born:

Chief Financial Officer & Executive Director
Mr. Vivek Valsaraj

Gender: male

Year Born: 1973

Head of Investor Relations & Sustainability
Mr. Gagan Borana

Gender: male

Year Born:

Senior Vice President of Operations
Vinay Agarwal

Gender: Not Specified

Year Born: 1964

Executive Chairperson
Ms. Nandini Ajay Piramal

Gender: female

Year Born: 1980

FAQs about Piramal Pharma Limited

Who is the CEO of the company?

The CEO is Peter Daniel DeYoung.

What is the current market price of the stock?

The current price is ₹187.49.

What is the 52-week price range?

The range is ₹181.73-283.9.

What is the market capitalization of the company?

The market capitalization is ₹24,806.18 crores.

What is the dividend yield?

The dividend yield is 0.07%.

What is the Price-to-Earnings (P/E) ratio?

The P/E ratio is -1,043.25.

Which sector does the company belong to?

The company operates in the Healthcare sector.

What does the company do?

Overview of Piramal Pharma Limited (ISIN: INE0DK501011) is a leading Biotechnology in India. With a market capitalization of ₹24,806.18 crores and an average daily volume of 3,562,529 shares, it operates in the Biotechnology. The company last declared a dividend of ₹0.14.